Revvity Launches High-Throughput T-SPOT.TB Platform for Clinical Labs

Revvity Unveils T-SPOT A201: A New Era in Tuberculosis Testing

Revvity, Inc. has recently introduced the T-SPOT A201, a next-generation high-throughput automated platform designed to support large-volume clinical laboratories conducting latent tuberculosis (TB) testing. Scheduled for launch in the second half of 2027, this platform is engineered to deliver the performance benefits of the T-SPOT.TB assay while enhancing workflow efficiency and scalability in high-throughput testing environments.

According to company management, the T-SPOT A201 represents a significant advancement in expanding access to the advantages of T-SPOT.TB testing for high-volume laboratories. The company believes that this solution will provide the necessary performance, workflow efficiency, and competitive economics for high-volume clinical labs, reinforcing its commitment to delivering scalable automation technologies for infectious disease diagnostics.

Market Reaction and Financial Outlook

Following the announcement, RVTY shares increased by 2.4% at yesterday’s close. Year to date, the stock has risen by 16.9%, outperforming the industry's 1.8% decline and the S&P 500's 7.4% gain. The development of the T-SPOT A201 platform is expected to strengthen Revvity’s infectious disease diagnostics and laboratory automation portfolio. By addressing the growing need for high-throughput latent TB testing, the company can enhance its position among large clinical laboratories while expanding opportunities within public health and diagnostic markets. Upon successful commercialization, the platform could drive broader adoption of Revvity’s automation solutions, support long-term customer relationships, and contribute to sustained revenue growth.

Revvity currently has a market capitalization of $12.33 billion.

Expanding Automation Solutions

The T-SPOT A201 expands Revvity’s portfolio of automation solutions that simplify the T-SPOT.TB workflow without compromising clinical performance. The company already offers the FDA-approved and CE-IVD-marked Auto-Pure 2400 liquid handler for laboratories with lower testing volumes. Designed to process up to 24 samples per run, the Auto-Pure 2400 completes first-day T-SPOT.TB workflows in less than 3.5 hours with minimal user interaction while delivering low indeterminate results, high sensitivity and specificity, extended sample stability, and efficient sample handling. These capabilities enable laboratories of different sizes to improve workflow efficiency while maintaining confidence in latent TB test results.

Built on the success of the Auto-Pure 2400 liquid handling platform, the T-SPOT A201 is designed to process up to 384 samples per instrument during an eight-hour shift while requiring only 45 seconds of hands-on time per sample. The platform is expected to help laboratories manage rising testing volumes driven by immigration screening, pre-treatment evaluations for immunosuppressive therapies, and broader public health initiatives, while supporting timely and accurate latent TB detection.

Industry Prospects and Growth Opportunities

According to data from Precedence Research, the U.S. tuberculosis diagnostics market is predicted to be valued at $607.5 million in 2026 and is expected to witness a CAGR of 5.3% through 2035. Factors such as the increasing adoption of rapid molecular and nucleic acid amplification tests, growing focus on detection of latent and drug-resistant tuberculosis, rising emphasis on automation, digital reporting, and laboratory workflow efficiency, and continued reliance on government funding and public health laboratory networks for TB testing programs are boosting the market’s growth.

Additional Developments and Strategic Moves

Revvity recently announced the launch of Signals for Startups, a new program to help early-stage biotechnology companies establish scalable digital informatics capabilities from the earliest stages of research. It is scheduled to launch across the United States, Europe, the Middle East, and the Africa region in late July 2026.

Additionally, Revvity announced that its Signals Software business has been added to Anthropic’s directory for Model Context Protocol connectors, extending the capabilities of Signals AI beyond the Signals One platform. Through the integration, scientists can access Signals AI and connected R&D knowledge using Claude, including Claude Science, Anthropic’s AI workbench for scientific research.

Stock Performance and Investment Insights

Revvity Inc. price | Revvity Inc. Quote

Revvity currently carries a Zacks Rank #5 (Strong Sell). Some better-ranked stocks from the broader medical space include West Pharmaceutical (WST), McKesson (MCK), and Cardinal Health (CAH), each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

West Pharmaceutical reported second-quarter 2026 adjusted earnings per share (EPS) of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

McKesson reported a fourth-quarter fiscal 2026 adjusted EPS of $11.69, which beat the Zacks Consensus Estimate by 1.1%. Revenues of $96.3 billion missed the Zacks Consensus Estimate by 5.5%.

Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.

Share :